| 1 |
Xiao H, Hu J, Huang C, Feng W, Liu Y, Kumblathan T, Tao J, Xu J, Le XC, Zhang H. CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. Trends Analyt Chem 2023;161:117000. [PMID: 36937152 DOI: 10.1016/j.trac.2023.117000] [Reference Citation Analysis]
|
| 2 |
de Menezes MT, Moreira FRR, Whittaker C, Santos FM, Queiroz DC, Geddes V, Fonseca PLC, de Jesus JG, Mendes-Oliveira F, Reis-Souza V, Santos B, Zauli DAG, de Lima AB, de Brito Mendonça C, Alvim LB, do Prado Silva J, Malta FSV, de Souza Ferreira AC, Faria NR, Sabino EC, Aguiar RS. Dynamics of Early Establishment of SARS-CoV-2 VOC Omicron Lineages in Minas Gerais, Brazil. Viruses 2023;15. [PMID: 36851799 DOI: 10.3390/v15020585] [Reference Citation Analysis]
|
| 3 |
Yang D, Weng H, Wang R, Li Y, Zhang H, Shao S, Huang H, Song Y, Chen X, Hou D, Wu Y, Lu X, Yang W, Chen Z, Hu X, Xuan J, Bai C, Wang Y. Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai. Front Med (Lausanne) 2023;10:1079165. [PMID: 36844224 DOI: 10.3389/fmed.2023.1079165] [Reference Citation Analysis]
|
| 4 |
Wurtz N, Boussier M, Souville L, Penant G, Lacoste A, Colson P, La Scola B, Aherfi S. Simple Wastewater Preparation Protocol Applied to Monitor the Emergence of the Omicron 21L/BA.2 Variant by Genome Sequencing. Viruses 2023;15. [PMID: 36851484 DOI: 10.3390/v15020268] [Reference Citation Analysis]
|
| 5 |
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses 2023;15. [PMID: 36680207 DOI: 10.3390/v15010167] [Reference Citation Analysis]
|
| 6 |
Suardana IBK, Mahardika BK, Pharmawati M, Sudipa PH, Sari TK, Mahendra NB, Mahardika GN. Whole-Genome Comparison of Representatives of All Variants of SARS-CoV-2, Including Subvariant BA.2 and the GKA Clade. Adv Virol 2023;2023:6476626. [PMID: 36938489 DOI: 10.1155/2023/6476626] [Reference Citation Analysis]
|
| 7 |
Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, Dung DV, Hwang KP, Ortiz Ibarra J, Kiertiburanakul S, Kulkarni PS, Lee C, Lee PI, Lobo RC, Macias A, Nghia CH, Ong-Lim AL, Rodriguez-Morales AJ, Richtmann R, Safadi MAP, Satari HI, Thwaites G. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines 2023;22:1-16. [PMID: 36330971 DOI: 10.1080/14760584.2023.2143347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, Chui CSL, Li X, Wong CKH, Lau CS, Wong ICK, Chan EWY. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med 2022;29. [PMID: 36250571 DOI: 10.1093/jtm/taac119] [Reference Citation Analysis]
|
| 9 |
Wu H, Liao K, Yang C, Zhou N, Dou H, Xu Z, Chu L, Song C, Luo C. Psychological experience of Juvenile patients’ parents in Fangcang shelter hospital during the Omicron wave of COVID-19 pandemic in Shanghai, China: a qualitative study. BMC Public Health 2022;22:2203. [DOI: 10.1186/s12889-022-14689-2] [Reference Citation Analysis]
|
| 10 |
Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Miyauchi S, Hiyama T, Nakano Y, Yoshino A, Miyake Y, Okamoto Y. Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy. Am J Infect Control 2022:S0196-6553(22)00813-6. [PMID: 36435404 DOI: 10.1016/j.ajic.2022.11.015] [Reference Citation Analysis]
|
| 12 |
Sarkar MS, Madabhavi I. SARS-CoV-2 variants of concern: a review. Monaldi Arch Chest Dis 2022. [DOI: 10.4081/monaldi.2022.2337] [Reference Citation Analysis]
|
| 13 |
Kherabi Y, Launay O, Luong Nguyen LB. COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. Viruses 2022;14:2086. [DOI: 10.3390/v14102086] [Reference Citation Analysis]
|
| 14 |
Seo JM, Kang B, Song R, Noh H, Kim C, Kim JI, Kim M, Ryu DK, Lee MH, Yang JS, Kim KC, Lee JY, Lee H, Woo HM, Kim JW, Choi JA, Song M, Tomaszewska-Kiecana M, Wołowik A, Kulesza A, Kim S, Ahn K, Jung N, Lee SY. Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerg Microbes Infect 2022;:1-39. [PMID: 36006772 DOI: 10.1080/22221751.2022.2117094] [Reference Citation Analysis]
|
| 15 |
Gladkikh A, Dedkov V, Sharova A, Klyuchnikova E, Sbarzaglia V, Arbuzova T, Forghani M, Ramsay E, Dolgova A, Shabalina A, Tsyganova N, Totolian A. Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. Microorganisms 2022;10:1676. [PMID: 36014093 DOI: 10.3390/microorganisms10081676] [Reference Citation Analysis]
|
| 16 |
Cai J, Hu S, Lin Q, Ren T, Chen L. China's 'dynamic zero COVID-19 strategy' will face greater challenges in the future. J Infect 2022;85:e13-4. [PMID: 35447231 DOI: 10.1016/j.jinf.2022.04.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 17 |
Bazargan M, Elahi R, Esmaeilzadeh A. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. J Gene Med 2022;:e3435. [PMID: 35726542 DOI: 10.1002/jgm.3435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
K A, Sharma A, Kumar D, Singh SK, Gupta G, Chellappan DK, Dua K, Nagraik R. Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. J Med Virol 2022. [PMID: 35705439 DOI: 10.1002/jmv.27936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol Spectr 2022;:e0153822. [PMID: 35658571 DOI: 10.1128/spectrum.01538-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 20 |
Nan B, Zhang S, Li Y, Kang X, Chen Y, Li L, Jiang T, Li J. Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants. Viruses 2022;14:1072. [DOI: 10.3390/v14051072] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Yuan M, Chen X, Zhu Y, Dong X, Liu Y, Qian Z, Ye L, Liu P. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.. [DOI: 10.1101/2022.05.11.491588] [Reference Citation Analysis]
|
| 22 |
Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, Zhang L. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:143. [PMID: 35487886 DOI: 10.1038/s41392-022-00986-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 23 |
Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther 2022;7:141. [PMID: 35484110 DOI: 10.1038/s41392-022-00997-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 24 |
Zhang J, Ejikemeuwa A, Gerzanich V, Nasr M, Tang Q, Simard JM, Zhao RY. Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19. Front Microbiol 2022;13:854567. [PMID: 35356515 DOI: 10.3389/fmicb.2022.854567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 25 |
González-domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, Mccroskery S, Coughlan L, Krammer F, García-sastre A, Palese P, Sun W. Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.. [DOI: 10.1101/2022.03.21.485247] [Reference Citation Analysis]
|
| 26 |
Rao Us V, Arakeri G, Rao U, Chandru V, Amaral Mendes R. We need to optimise genome surveillance and tracing of SARS-CoV-2 variants. BMJ 2022;376:o601. [PMID: 35277422 DOI: 10.1136/bmj.o601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Xu Z, Zeng Q. More or less deadly? A mathematical model that predicts SARS-CoV-2 evolutionary direction.. [DOI: 10.1101/2022.03.10.483726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Dhawan M, Priyanka, Choudhary OP. Emergence of Omicron sub-variant BA.2: Is it a matter of concern amid the COVID-19 pandemic? Int J Surg 2022;99:106581. [PMID: 35202859 DOI: 10.1016/j.ijsu.2022.106581] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 29 |
Mahase E. Covid-19: What do we know about omicron sublineages? BMJ 2022;376:o358. [PMID: 35149516 DOI: 10.1136/bmj.o358] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 30 |
Mahase E. Covid-19: Past infection may not protect against future variants, researcher warns. BMJ 2022;376:o334. [PMID: 35131806 DOI: 10.1136/bmj.o334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
